Drugmaker Dishman Pharmaceuticals and Chemicals reported a 31.8% dip in consolidated annual net profit on mounting raw material and operational costs.
The bulk drugmaker and contract researcher on Thursday reported a consolidated net profit of Rs 80.01 crore for FY11 on net sales of Rs 991 crore.
Although Dishman Pharma's consolidated sale grew about 7% in the year, a substantial rise in raw material costs and operational expenses hurt profit.
"The company's Swiss subsidiary is bleeding and that is actually hitting the company's performance," Siddhant Khandekar, analyst at ICICI Securities, said.
Dishman's raw material cost rose 26.3% to Rs 293 crore in FY11, while its spend on purchase of traded goods more-than-doubled to Rs 90.12 crore. Its employee cost also rose about 10% to Rs 280 crore for the year ended March 31, it said.
"The CRAMS (contract research and manufacturing services) business is seeing slow recovery but that won't help Dishman much considering the rising costs," he added.
Shares of Dishman Pharmaceuticals ended at Rs 95.50 on Thursday, up 3.75% in a firm Mumbai market.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
